Ziab

Ziab provides affordable, consistent single-domain antibodies (nanobodies) to accelerate biological research in neuroscience, cancer, and complex models. The company uses a proprietary AI platform combined with bioinformatics, proteomics analysis, and automated recombinant production to design and produce nanobodies with improved tissue penetration and novel target access. Ziab operates as a mix of SaaS, custom development, and product sales to serve life-science researchers, biotechnology companies, and pharmaceutical firms. Key technologies include AI-driven design, nanobody engineering, recombinant expression, and automation. Their approach reduces development time and cost compared with traditional antibody discovery methods and targets applications in research, diagnostics, and therapeutics.